Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06802718 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

StatusRecruiting
PhasePhase 3
Started2023-01-01
View on ClinicalTrials.gov ↗
This research focuses on a prospective, randomized, controlled trial of "Interferon-alpha as maintenance therapy for favorable-risk acute myeloid leukemia." By fully utilizing prospective, randomized, controlled clinical trial and studying the negative conversion of MRD and the survival of favorable-risk AML patients, it aims to explore the efficacy and safety of Interferon-alpha in the maintenance treatment of favorable-risk AML and identify effective measures to prevent relapse, thereby improving the survival of favorable-risk AML patients. The primary endpoint is the negative conversion of MRD at 6 months. The secondary endpoints include the 2-year cumulative incidence of relapse, 2-year event-free survival (EFS), 2-year overall survival (OS), and safety.
Trial Details
NCT Number NCT06802718
Lead Sponsor Peking University People's Hospital
Conditions Acute Myeloid Leukemia
Enrollment 96 participants
Start Date 2023-01-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-31